AtriCure, Inc.
NASDAQ:ATRC · NASDAQ Global Market
+$0.96 today
Vol 1.60M · Avg 0.77M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ATRC · Revenue to Net Income
Key Ratios
Analysis
$552.2M of revenue converted into -$4.6M of net income for the selected period. Gross margin is 75.5% and net margin is -0.9%, showing how much revenue survives after costs and taxes. EPS is $-0.10, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $534.5M +14.9% | $465.3M +16.5% | $399.2M +20.8% | $330.4M +20.4% | $274.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $136.8M +16.1% | $117.8M +19.1% | $98.9M +17.1% | $84.4M +23.3% | $68.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $397.7M +14.4% | $347.5M +15.7% | $300.4M +22.1% | $245.9M +19.5% | $205.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 74.4% -0.3pp | 74.7% -0.5pp | 75.2% +0.8pp | 74.4% -0.6pp | 75.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $90.2M -6.2% | $96.2M +30.1% | $73.9M +28.9% | $57.3M +18.2% | $48.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $311.0M +6.7% | $291.4M +15.1% | $253.1M +9.5% | $231.3M +13.0% | $204.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $401.2M +3.5% | $387.5M +18.5% | $327.1M +13.3% | $288.6M +91.6% | $150.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $20.5M +9.6% | $18.7M +26.5% | $14.8M +26.5% | $11.7M +12.2% | $10.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $16.2M +187.7% | -$18.5M -128.6% | -$8.1M +72.5% | -$29.5M -144.9% | $65.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 3.0% +7.0pp | -4.0% -2.0pp | -2.0% +6.9pp | -8.9% -32.9pp | 24.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$3.4M +91.4% | -$40.0M -50.0% | -$26.7M +37.5% | -$42.7M -177.3% | $55.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -0.6% +8.0pp | -8.6% -1.9pp | -6.7% +6.2pp | -12.9% -33.0pp | 20.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.5M +1.0% | $4.4M +16.9% | $3.8M +90.2% | $2.0M +327.9% | $466.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.9M -8.3% | $6.4M -7.5% | $6.9M +38.9% | $5.0M +1.4% | $4.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$6.7M -83.4% | -$3.7M -15.7% | -$3.2M +10.3% | -$3.5M +26.8% | -$4.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$10.2M +76.7% | -$43.7M -46.3% | -$29.8M +35.4% | -$46.2M -191.7% | $50.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1.9% +7.5pp | -9.4% -1.9pp | -7.5% +6.5pp | -14.0% -32.4pp | 18.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.3M +25.5% | $1.0M +73.3% | $591.0K +120.5% | $268.0K +42.6% | $188.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$11.4M +74.4% | -$44.7M -46.8% | -$30.4M +34.5% | -$46.5M -192.6% | $50.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -2.1% +7.5pp | -9.6% -2.0pp | -7.6% +6.4pp | -14.1% -32.4pp | 18.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +74.7% | -$1 -43.9% | -$1 +35.3% | -$1 -191.9% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +74.7% | -$1 -43.9% | -$1 +35.3% | -$1 -193.6% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $47.8M +1.7% | $47.0M +1.4% | $46.3M +1.2% | $45.7M +1.5% | $45.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $47.8M +1.7% | $47.0M +1.4% | $46.3M +1.2% | $45.7M -0.6% | $46.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
10x Genomics, Inc.
NASDAQ:TXG
$4.48B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.14B
Select Medical Holdings Corporation
NYSE:SEM
$2.05B
NovoCure Limited
NASDAQ:NVCR
$1.70B
Immunocore Holdings plc
NASDAQ:IMCR
$1.46B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.26B
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$1.20B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.12B
Azenta, Inc.
NASDAQ:AZTA
$1.05B
QuidelOrtho Corporation
NASDAQ:QDEL
$899.10M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ATRC generate?
AtriCure, Inc. (ATRC) reported $534.53M of revenue in fiscal 2025.
Is ATRC profitable?
AtriCure, Inc. (ATRC) reported -$11,448,000.00 of net income, with a net margin of -2.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.